Go Digit General vs Niva Bupa Health Q4 FY26

Go Digit reported a strong Q4 FY26 with gross direct premium of 11,300 crore, up 16.2% YoY, and PAT of 1,759 crore (up 49% YoY). The combined ratio improved to 105.7% (down 1.2pp YoY). Growth was driven by two-wheeler (up 52% to 556 crore) and fire segments, while health reinsurance was dropped due to poor profitability. The company transitioned to Indian Accounting Standards (IFRS-aligned) and reported an ROE of 17.7%. Management guided for continued focus on underwriting discipline, new specialty lines, and expects regulatory action on expense management to benefit the industry. Key risk: sustained competitive pressure in motor and health segments could pressure margins.

Guidance read

New specialty lines target 1,000 Cr premium in 3-5 years: Management plans to develop niche commercial lines, aiming for ~1,000 crore premium over 3-5 years. Motor OD loss ratio to stabilize by Q2 FY27: Corrective actions taken in Q4 should stabilize motor OD loss ratio by July-September 2026, then reduce. Crop insurance direct participation in FY27: Company plans to participate directly in crop insurance tenders in FY27, building on capability development.

Risk read

Key risks include Motor TP price hike delay — No TP price hike for fifth consecutive year; industry loss ratios may remain under pressure.; EUM regulatory compliance — Company's EUM is above peers due to business mix; regulatory action on expense management may impact growth.; Fire segment net loss ratio deterioration — Net loss ratio in fire increased due to two large claims; gross ratio stable but net impacted by reinsurance costs..

Promise ledger

Scorecard data is being built as historical quarters are processed.

Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.

Guidance read

Combined ratio target of ~99% by FY29: Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps. Retail health industry growth of 17-19% CAGR over 5 years: Management reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon. Loss ratio may inch up by ~150 bps: Management guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.

Risk read

Key risks include Potential commission cap regulation — Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.; Normalization of GST-driven growth — Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.; Group health loss ratio volatility — Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk..

Promise ledger

Scorecard data is being built as historical quarters are processed.